Relevant bibliographies by topics / Vaccino HPV

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Vaccino HPV'

Author: Grafiati
Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Vaccino HPV.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Vaccino HPV"

1

Longo, Giorgio. "Domande e risposte." Medico e Bambino 39, no. 9 (November 9, 2020): 605. http://dx.doi.org/10.53126/meb39605.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Caso, Daniela. "L'accettabilitŕ del vaccino contro il Papilloma Virus (HPV): fattori psicosociali che incidono sulla scelta delle madri." PSICOLOGIA DELLA SALUTE, no. 1 (May 2011): 83–99. http://dx.doi.org/10.3280/pds2011-001007.

Full text
Abstract:
L'Italia č stato il primo paese europeo a pianificare una strategia di vaccinazione pubblica contro l'HPV, l'agente virale responsabile del carcinoma della cervice uterina, primo tumore riconosciuto dall'OMS come totalmente riconducibile ad una infezione, proponendo il vaccino alle ragazze nel dodicesimo anno di vita. Con l'avvio della somministrazione di tale vaccino sono sorti dubbi e perplessitŕ riguardo la sua efficacia, i suoi effetti e soprattutto sulla sua possibile accettazione. Pertanto questo studio, che ha coinvolto 507 madri napoletane con figlie dodicenni, si pone l'obiettivo di indagare il ruolo che alcune variabili psicosociali (conoscenze, aspettative di risultato, percezione del rischio, intenzioni, autoefficacia genitoriale ed efficacia familiare) hanno sull'accettazione del vaccino da parte delle madri. Dall'analisi dei dati, raccolti con un questionario self-report, sono emersi profili differenziati delle intervistate in funzione della loro scelta verso il vaccino HPV. Ciň potrebbe avere utili implicazioni nelle campagne di prevenzione in favore degli screening vaccinali, suggerendo di adottare strategie differenziate a seconda delle caratteristiche delle donne da contattare.
APA, Harvard, Vancouver, ISO, and other styles
3

Ghini, Teresa, Cesare Cutrone, Martina Bertinazzi, Marianna Sari, and Antonella Brunelli. "Vaccino HPV e papillomatosi respiratoria ricorrente giovanile: un possibile nuovo uso per un vecchio vaccino." QUADERNI ACP 28, no. 5 (2021): 229. http://dx.doi.org/10.53141/qacp.2021.229-232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

ODONE, A., S. VISCIARELLI, T. LALIC, F. PEZZETTI, F. SPAGNOLI, C. PASQUARELLA, G. FERRARI, and C. SIGNORELLI. "Carcinomi associati al papillomavirus umano: conoscenze, ruolo e attitudini dei medici otorinolaringoiatri in tema di prevenzione." Acta Otorhinolaryngologica Italica 35, no. 6 (December 2015): 379–85. http://dx.doi.org/10.14639/0392-100x-621.

Full text
Abstract:
L’infezione da papillomavirus umano (HPV), in particolare HPV 16, è un riconosciuto fattore causale delle neoplasie orofaringee. L’incidenza delle neoplasie orofaringee è in aumento in diversi paesi europei, inclusa l’Italia, e negli Stai Uniti dove accurati modelli matematici hanno stimato che supererà quella del cancro alla cervice nella prossima decade. Recenti evidenze scientifiche supportano la potenziale efficacia del vaccino anti-HPV nel controllare quella che è stata definita “l’epidemia di neoplasie HPV-correlate”. In questo contesto, i medici otorinolaringoiatri assumono un ruolo cruciale, non solo nella diagnosi e trattamento di questa patologia, ma anche – come è stato sottolineato dall’American Head and Neck Society – nella prevenzione. Abbiamo condotto un’indagine sulle conoscenze e le attitudini dei medici otorinolaringoiatri italiani in tema di infezione HPV, patologie correlate e prevenzione vaccinale. Si tratta della prima indagine conoscitiva in Italia e in Europa sull’argomento. 262 medici otorinolaringoiatri italiani sono stati reclutati durante il 101° Congresso Nazionale della Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale, tenutosi in maggio 2014. È stato utilizzato un questionario semi-strutturato sviluppato sulla base delle evidenze disponibili in letteratura e del parere di esperti. Le conoscenze e le attitudini sono state descritte e valutate con tecniche di analisi univariata. È stato inoltre costruito uno score composito di conoscenza. I dati dimostrano come i medici otorinolaringoiatri italiani abbiano, in media, un grado di conoscenza buono dell’infezione HPV e un’attitudine positiva nei confronti della prevenzione, in particolare della vaccinazione. I nostri risultati possono essere una utile base per pianificare, implementare e valutare programmi di educazione continua specifici sul tema della prevenzione dell’infezione da HPV. Come dimostriamo nel nostro studio, programmi di educazione continua specifici sono efficaci nell’aumentare il grado di conoscenza dei medici e l’attitudine positiva nei confronti dei programmi di prevenzione; il che contribuisce a promuovere l’adesione alla vaccinazione nei pazienti e nella popolazione generale. Con l’obiettivo generale di controllare l’epidemia di neoplasie HPV-correlate, maggiori risorse ed energie devono essere dedicate alla formazione e alla diffusione della cultura della prevenzione tra i medici otorinolaringoiatri e la comunità medica in generale. In questo contesto, identifichiamo grande potenziale nella collaborazione tra le comunità e le società scientifiche dell’otorinolaringoiatria e la sanità pubblica.
APA, Harvard, Vancouver, ISO, and other styles
5

Buxton, Jane A., and Jin Hee Kim. "Hepatitis A and Hepatitis B Vaccination Responses in Persons with Chronic Hepatitis C Infections: A Review of the Evidence and Current Recommendations." Canadian Journal of Infectious Diseases and Medical Microbiology 19, no. 2 (2008): 197–202. http://dx.doi.org/10.1155/2008/410362.

Full text
Abstract:
In persons with chronic hepatitis C virus (HCV) infections, superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) can cause serious complications, including fulminating hepatitis or increased severity of hepatitis. Therefore, it is important to adequately protect persons with chronic HCV infections by immunization. Suboptimal response to vaccines has been reported in patients with chronic liver disease. The present article reviews HAV and HBV vaccine responses reported in the literature when administered to individuals with chronic HCV infection, and reviews current national and international recommendations.RESULTS: Persons with chronic HCV respond well to HAV vaccine, but studies exploring HBV vaccine efficacy in this population have equivocal results. Vaccine schedules and participant characteristics differ among studies, and most do not adjust for confounders. Some studies found no difference in HBV vaccine response between patients with chronic HCV and controls. However, HBV vaccine response was generally reduced in those with cirrhosis and HCV genotype 1. Organizations recommend HAV and HBV vaccines for persons with chronic HCV, but do not suggest alterations in schedule or dose.RECOMMENDATIONS: Because HAV vaccine response is good and routine laboratory testing may not detect lower levels of vaccine-induced anti-HAV, the standard HAV vaccine schedule is recommended without postimmunization testing. HBV vaccine should be administered early in the course of chronic HCV infection because response may be lower in patients with cirrhosis. Reflex testing of anti-HCV reactive sera for anti-HAV and hepatitis B surface antibody can facilitate appropriate follow-up and timely immunization. Determination of postimmunization hepatitis B surface antibody, especially in patients with cirrhosis or genotype 1, will allow HBV vaccine boosters to be offered.
APA, Harvard, Vancouver, ISO, and other styles
6

Morbini, P., and M. Benazzo. "Papillomavirus umano e carcinomi del tratto aerodigestivo: il punto sulle evidenze nella babele dei dati scientifici." Acta Otorhinolaryngologica Italica 36, no. 4 (August 2016): 249–58. http://dx.doi.org/10.14639/0392-100x-853.

Full text
Abstract:
I carcinomi squamosi dell'orofaringe associati all'infezione da papillomavirus umano (HPV) costituiscono ormai una entità ben caratterizzata, che interessa prevalentemente maschi, giovani adulti o di mezza età, non fumatori. Essi hanno generalmente una prognosi più favorevole rispetto alla controparte non associate ad infezione, e per questo è stato proposto di dedicare a questo gruppo di pazienti un approccio terapeutico meno aggressivo. L'incidenza dei carcinomi dell'orofaringe associati a HPV è in rapido aumento nella maggior parte dei paesi occidentali, ma per quanto riguarda la popolazione italiana non sono disponibili dati epidemiologici in merito. Per quanto riguarda le altre regioni del distretto testa-collo, una più modesta porzione di lesioni displastiche di alto grado e di neoplasie appare essere correlata all'infezione da HPV, mentre il ruolo del virus nei tumori della laringe è stato parzialmente ridimensionato. HPV determina la trasformazione neoplastica delle cellule infettate tramite l'espressione dei suoi due oncogeni, E6 ed E7, che interagiscono con i meccanismi di apoptosi e regolazione del ciclo cellulare della cellula ospite. L'unica metodica in grado di documentare con certezza l'espressione degli oncogeni virali è attualmente l'amplificazione dell'RNA messaggero trascritto dai due oncogeni. Il consenso riguardo la strategia per l'identificazione dei pazienti affetti da carcinoma dell'orofaringe associato a HPV dal punto di vista clinico e diagnostico è tuttora limitato. Le metodiche diagnostiche più utilizzate, singolarmente o in combinazione, comprendono l'immunocolorazione con anticorpi diretti contro p16, l'ibridazione in situ per genotipi virali ad alto rischio e l'amplificazione del DNA virale mediate PCR. La possibilità di ottenere una diagnosi precoce grazie all'identificazione dell'infezione virale nelle cellule epiteliali esfoliate dal cavo orale o dall'orofaringe non ha finora fornito risultati soddisfacenti, tuttavia la persistenza del virus nel cavo orale in pazienti trattati per carcinoma dell'orofaringe ha dimostrato una significativa associazione con il rischio di recidiva del tumore. Non sono ancora disponibili sufficienti dati che documentino in maniera dettagliata la storia naturale dell'infezione a la sua progressione verso lo sviluppo di una neoplasia, e che definiscano con chiarezza le modalità di trasmissione e i fattori di rischio, comunque è chiaro che i comportamenti sessuali hanno un peso rilevante nel determinare il rischio di sviluppo di neoplasia dell'orofaringe HPV-correlata. La progressive diffusione nelle giovani generazioni del vaccino contro HPV, e soprattutto la sua estensione agli adolescenti di entrambi i generi è sicuramente destinata a modificare in maniera rilevante anche l'epidemiologica dei tumori HPV-correlati nel distretto testa-collo nel prossimo futuro.
APA, Harvard, Vancouver, ISO, and other styles
7

Cavallo, Maria Caterina, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, and Francesco Bamfi. "L’introduzione del vaccino anti-HPV bivalente adiuvato con AS04 nelle regioni italiane: impatto economico ed effetti sulla salute delle donne." Farmeconomia. Health economics and therapeutic pathways 9, no. 1S (September 15, 2008): 3–10. http://dx.doi.org/10.7175/fe.v9i1s.998.

Full text
Abstract:
Introduction: the impact of cervical cancer prevention, in particular through HPV female vaccination, has been published for many countries at the national level. However, to our knowledge no attempt has been made to address the impact at a regional level. Since the Italian health reforms of the early 1990s, introducing “managerialism”, decentralization and quasi-market mechanisms, regional authorities have consequently been experimenting with different organizational and funding models to achieve an acceptable combination of equity, efficiency, freedom of choice and cost-containment. Methods: a Markov model, previously described and successfully adapted to the national scenario [La Torre, 2007], has been used to explore the impact of preventive cervical cancer vaccination with Cervarix™ at a regional level in Italy. Resource use was based on a standard therapeutic path applied to all regions. However we quantified the impact of the so-called “decentralization progress” by collecting regional data on: pap-test coverage, tariffs for treatments and cost of the vaccination course. We performed for each Italian region a cost-effectiveness analysis combined with a regional budget impact analysis. The regional analyses compared HPV vaccination, both of a single female cohort (12 years old) and a multiple female cohort (12+16 years old), plus screening to screening only. Results: 21 regional reports were produced presenting regional results on screening coverage, treatments costs, ICER and ICUR, net cost per subject vaccinated etc. Conclusions: national and regional analyses have two different aims: the former wants to address national regulatory agencies and needs to be representative of the national population whereas the latter deals with the real budget-holders, accountable in the eyes of patients. Furthermore in the Italian scenario, characterized by decentralization and local autonomy, a further level of detail is essential in order to describe the specific local settings and implications of a new health intervention.
APA, Harvard, Vancouver, ISO, and other styles
8

Toft, Lars, Martin Tolstrup, Merete Storgaard, Lars Østergaard, and Ole S. Søgaard. "Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives." Sexual Health 11, no. 6 (2014): 511. http://dx.doi.org/10.1071/sh14015.

Full text
Abstract:
Background Men and women with HIV infection are at increased risk of developing cancers associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines protect against de novo infection with HPV-16 and HPV-18, which cause the majority of HPV-associated cancers. Currently, no vaccine efficacy data are available for persons with HIV infection. Nevertheless, some countries have implemented specific HPV vaccination recommendations for HIV-positive populations. To specifically recommend prophylactic HPV vaccination in people with HIV, the vaccines must be safe and immunogenic in immunosuppressed people at a high risk of HPV infection. This review aims to summarise the current knowledge from published HPV vaccine trials in HIV-infected populations, to compile scheduled and ongoing HPV vaccine trials with HIV-positive study populations and to extrapolate the relevant knowledge about HPV vaccine efficacy in HIV-negative populations to an HIV context. Methods: The databases PubMed, Scopus and ClinicalTrials.gov were searched for peer-reviewed articles and scheduled or ongoing clinical HPV vaccine trials enrolling HIV-positive persons. Results: Current data indicate that prophylactic HPV vaccines are safe and immunogenic in different HIV-positive populations (children, female adolescents, adults). Increased immunogenicity has been reported in persons on antiretroviral therapy compared with antiretroviral-naïve persons, whereas no clear association has been found between CD4+ cell count at immunisation and vaccine response. Several scheduled and ongoing HPV vaccine trials aim to determine vaccine efficacy against disease endpoints in HIV-infected study populations. Conclusion: Prophylactic HPV vaccination appears safe, immunogenic and, by extrapolation, likely to reduce HPV-associated cancer development among persons with HIV infection.
APA, Harvard, Vancouver, ISO, and other styles
9

Heffernan, Margaret E., Suzanne M. Garland, and Mark A. Kane. "Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience." Sexual Health 7, no. 3 (2010): 383. http://dx.doi.org/10.1071/sh09134.

Full text
Abstract:
Background: Worldwide, prophylactic vaccines against two major human cancers are now commercially available: hepatitis B virus (HBV) vaccines (first licensed in 1982) against primary hepatocellular carcinoma and human papillomavirus (HPV) vaccines (first licensed 2006) against cervical cancer. Initial implementation strategies for HBV vaccination were not successful in preventing disease in the community: it took 15 years for significant global reduction in the burden of this disease. Methods: We compare and contrast HBV vaccine experiences to challenges for successful global HPV vaccination strategies, and make recommendations accordingly. Results: Lessons from HBV immunisation for successful outcomes with HPV immunisation showed that several factors need to be met: (i) the engagement of key stakeholders in all aspects of planning and delivery of HPV vaccine strategies; (ii) understanding the specific characteristics of targeted population groups; (iii) global cooperation and support with WHO recommendations; (iv) Government supported mass immunization programs and cooperation between public and private entities; (v) affordable HPV vaccines for some regions; (vi) culturally appropriate and diverse public education programs in targeted health promotion strategies; (vii) pro-active health providers and parents in encouraging adolescents to undertake HPV vaccination; and (vii) eventual immunisation of infants. Conclusions: The key to success will be affordable, readily deliverable HPV vaccines to young girls as universal campaigns.
APA, Harvard, Vancouver, ISO, and other styles
10

Fang, Lily, Amanda Yu, and Jane A. Buxton. "Identification of Acute Vaccine-Preventable Hepatitis in Individuals with Chronic Hepatitis in British Columbia between 1991 and 2007." Canadian Journal of Infectious Diseases and Medical Microbiology 22, no. 1 (2011): 10–14. http://dx.doi.org/10.1155/2011/564290.

Full text
Abstract:
BACKGROUND: In British Columbia (BC), hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccines are provincially funded for persons with chronic hepatitis infections. PURPOSE: To assess the effectiveness of BC public health follow-up of HBV and hepatitis C virus (HCV) cases and immunization policy by determining the number of vaccine-preventable acute hepatitis infections reported following a chronic HBV or HCV diagnosis, by examining demographic characteristics and by observing temporal trends.METHODS: All newly identified cases of HAV, HBV and HCV between 1991 and October 2007 were extracted from the BC integrated Public Health Information System and linked to ascertain cases of hepatitis suprainfection.RESULTS: Between 1991 and October 2007, 30 BC residents with chronic HBV and 104 with HCV were subsequently diagnosed with HAV. Acute HBV was identified in 162 persons previously diagnosed with HCV. Significantly more men than women developed hepatitis suprainfection (P<0.0001), but women were of a younger age when they were diagnosed with HAV (P=0.02) and acute HBV (P=0.0002). HAV suprainfection cases among those with HCV peaked in 1998 at 33 cases and declined to zero cases in 2007. In comparison, HBV suprainfection among individuals with chronic HCV peaked in 1996 at 26 cases and declined to two cases in 2007.DISCUSSION: Cases of HAV and acute HBV have declined among HCV-infected individuals. However, despite the availability of publicly funded vaccines for high-risk groups, a substantial number of acute HBV infections post-HCV identification are still identified, indicating that follow-up and vaccination coverage should be improved in these populations.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Vaccino HPV"

1

Squarzon, Laura. "Evaluation of HPV type-specific antibody response induced by the prophylactic quadrivalent vaccine." Doctoral thesis, Università degli studi di Padova, 2013. http://hdl.handle.net/11577/3422903.

Full text
Abstract:
Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide and affects approximately 300 million new individuals each year. HPV is considered the primary etiological agent involved in the development of cervical cancer and causes half a million cases per year worldwide. Prevention of genital HPV infection through immunization has led investigators to employ a number of strategies to develop candidate HPV vaccines. Until today, two different vaccines are available on the market: a quadrivalent vaccine that protects against HPV types 16, 18, 6, and 11 (Gardasil®, Merck Sharp and Dohme), and a bivalent vaccine that protects against HPV types 16 and 18 (Cervarix™, Glaxo SmithKline). Current data regarding the efficacy of these vaccines derive mainly from studies performed by the manufacturers and standardized assays are not commercially available to measure HPV immunity. In this context, the aim of this PhD research project is to set up and standardize HPV pseudovirion-based neutralization (PBNA) and enzyme-linked immunosorbent (ELISA) assays and to use these tests to evaluate and compare the immunogenicity and cross-reactivity levels of the two prophylactic HPV vaccines, which are offered free in Italy to 12-year old girls and are recommended to women aged 12-45 years, according to World Health Organization (WHO) guidelines. First, pseudovirions of HPV types 6, 11, 16, 18, 31, 45, 52, 58 were obtained with a titer of 109 transducing units/ml and neutralization and ELISA assays standardized. Subsequently, a cross sectional study to evaluate the humoral immune response against HPV-volunteers, adolescents, and healthy vaccinated adults with Gardasil® or Cervarix™ was approved by ethics committee of University Hospital of Padua. Comprehensive results were obtained from a group of 100 subjects from Veneto Region, where the quadrivalent Gardasil® vaccine was offered. The study group included 81 subjects investigated within 1-6 months after the completion of the three doses of vaccine and 7, 7, and 5 subjects investigated at 2, 3, and 4 years after vaccination, respectively. At 1-6 months after the completion of the vaccination cycle, 100% vaccinees had neutralizing antibodies (NAbs) against HPV16, 98,8% had NAbs against HPV18, while 91% had NAbs against HPV6 and 50% had NAbs against HPV11. The NAbs titer ranged widely from 1:40 to over 1:10,240 and was lower for NAbs against HPV6 and HPV11 as compared with NAbs titers against HPV16 and HPV18. A progressive reduction of NAbs titer was observed over time and, at 4 years from vaccination, 80% of subjects had NAbs against HPV16, HPV18 and HPV6, and 60% against HPV11. Low level cross-NAbs titer against HPV31 (1:40) was detected in 50% (3/6) of subjects at 1-6 months after vaccination, while no cross-NAbs were detected against HPV45, HPV52 and HPV58. We also evaluated the presence of HPV type-specific NAbs in a group of 6 young girls vaccinated with CervarixTM at 1-6 months after the completion of the vaccination cycle. All subjects presented specific NAbs against HPV16 and HPV18. Titers were higher as compared with titers observed in Gardasil® vaccinated subjects. 100% of subjects presented also cross-NAbs against HPV31, whereas 16,6% presented cross-NAbs against HPV45 and HPV58. None presented cross-NAbs against HPV52. Thanks to these results we can conclude that high-level NAbs were induced with both Gardasil® and CervarixTM vaccines. For the first vaccine, we observed the decline of NAbs titers and the limited cross-neutralization against HPV31. For the second one, cross-neutralizing NAbs were observed against HPV31 in all subjects, together with the presence of NAbs against HPV45 and HPV58 in some subjects.
L'infezione da papilloma virus umano (HPV) è una delle più comuni infezioni trasmesse per via sessuale in tutto il mondo e colpisce circa 300 milioni di nuovi individui ogni anno. L’infezione persistente da tipi di HPV definiti ad alto rischio è la causa necessaria per lo sviluppo del cancro del collo dell’utero. Annualmente, vengono registrati circa 500.000 casi di carcinomi del collo dell’utero in tutto il mondo. La necessità di prevenire questo tipo di infezione ha portato nel corso degli ultimi anni allo sviluppo di diverse strategie vaccinali. Ad oggi, sono disponibili due diversi vaccini profilattici: un vaccino quadrivalente che protegge contro HPV16, 18, 6, e 11 (Gardasil®, Merck Sharp & Dohme), e un vaccino bivalente che protegge contro HPV 16 e 18 (Cervarix™, Glaxo SmithKline). I dati riguardanti l'efficacia e l’immunogenicità di questi due vaccini derivano principalmente da studi effettuati dalle ditte produttrici. Non sono disponibili inoltre test standardizzati commerciali in grado di valutare l'immunità nei confronti dei diversi tipi di HPV. Obiettivo di questo progetto di ricerca di dottorato è quello di sviluppare e standardizzare un test specifico per la ricerca di anticorpi anti-HPV basato sulla neutralizzazione di diversi tipi di HPV mediante pseudovirioni (PBNA) e un test immunoenzimatico (ELISA), e di utilizzare questi test per valutare e confrontare i livelli di immunogenicità e cross-reattività dei due vaccini profilattici anti-HPV che sono offerti gratuitamente in Italia alle ragazze nel loro dodicesimo anno di età e che vengono raccomandati per le donne di età compresa tra i 12 e i 45 anni, secondo le linee guida dell'Organizzazione Mondiale della Sanità (OMS). A tal fine, sono stati prodotti diversi lotti di pseudovirioni corrispondenti ai tipi HPV6, 11, 16, 18, 31, 45, 52, 58 con un titolo pari a 109 unità trasducenti/ml e sono stati standardizzati i saggi di neutralizzazione tipo-specifica e il saggio ELISA. E’ stato disegnato uno studio cross-sectional per valutare la risposta immunitaria umorale contro i diversi tipi di HPV in soggetti sani, adolescenti e adulti, vaccinati con Gardasil® o Cervarix™. I risultati sono stati ottenuti analizzando un gruppo di 100 soggetti della Regione Veneto, dove era offerta la vaccinazione con Gardasil®. In particolare, sono stati esaminati 81 soggetti a distanza di 1-6 mesi dal completamento del ciclo vaccinale, 7 soggetti valutati a 2 anni dalla vaccinazione, 7 soggetti a 3 anni dalla vaccinazione, e 5 a 4 anni dalla vaccinazione. A distanza di 1-6 mesi dal completamento della vaccinazione con Gardasil®, il 100% dei soggetti presentava anticorpi neutralizzanti contro HPV16, il 98,8% contro HPV18, il 91% contro HPV6 e il 50% contro HPV11. Sono stati ottenuti titoli di anticorpi neutralizzanti compresi tra 1:40 e 1:10,240. I titoli osservati nei confronti di HPV6 e HPV11 sono risultati inferiori rispetto a quelli osservati nei confronti di HPV16 e HPV18. E’ stata, inoltre, osservata una riduzione progressiva nel titolo in base al tempo intercorso dall’ultima dose vaccinale. A 4 anni dalla vaccinazione, l'80% dei soggetti presentava anticorpi neutralizzanti contro HPV16, HPV18 e HPV6, mentre il 60% nei confronti di HPV11. Per quanto riguarda la presenza di anticorpi cross-neutralizzanti, è stato osservato un titolo pari a 1:40 nei confronti di HPV31 nel 50% (3/6) dei soggetti entro i primi 6 mesi dalla vaccinazione, mentre non sono stati rilevati anticorpi cross-neutralizzanti nei confronti di HPV45, HPV52 e HPV58. E' stata valutata, inoltre, la presenza di anticorpi neutralizzanti nei confronti dei diversi tipi di HPV in un gruppo di 6 ragazze vaccinate con CervarixTM a distanza di 1-6 mesi dal completamento della vaccinazione. Tutti i soggetti presentavano anticorpi neutralizzanti nei confronti di HPV16 e HPV18, a titoli più elevati rispetto ai titoli osservati nei soggetti vaccinati con Gardasil®. Il 100% dei soggetti presentava, inoltre, anticorpi cross-neutralizzanti contro HPV31, mentre il 16,6% aveva anticorpi cross-neutralizzanti contro HPV45 e HPV58. Nessun soggetto ha presentato anticorpi cross-neutralizzanti contro HPV52. In conclusione, entrambi i vaccini sono in grado di indurre elevati livelli di specifici anticorpi neutralizzanti i tipi di HPV vaccinali. Per quanto riguarda il vaccino Gardasil® è stata osservata una diminuzione dei titoli anticorpali nel tempo e una limitata cross-neutralizzazione nei confronti di HPV31. Per quanto riguarda il vaccino CervarixTM, invece, è stata osservata la presenza di anticorpi cross-neutralizzanti contro HPV31 in tutti i soggetti, unitamente alla presenza degli anticorpi neutralizzanti contro HPV45 e HPV58 in alcuni soggetti.
APA, Harvard, Vancouver, ISO, and other styles
2

Fontes, Adriele Souza. "Resposta específica aos antígenos da vacina anti-HPV em homens infectados pelo HIV-1." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/99/99131/tde-03082015-103315/.

Full text
Abstract:
Introdução: A infecção pelo Papiloma Virus Humano (HPV) vem sendo reportada como uma das doenças sexualmente transmissíveis com maior incidência na atualidade, porém a sua prevalência não é bem esclarecida em homens, principalmente devido a baixa presença de sintomas. Além disso, poucos estudos foram realizados nesta população até o momento para verificar a resposta imune pós-vacinação. As hipóteses testadas serão fundamentais para aprofundar o conhecimento da imunopatogênese, da resposta vacinal em pacientes infectados pelo HIV e colaborar no desenho e estratégias de vacinação anti-HPV na população infectada pelo HIV Objetivos: Analisar a resposta específica aos antígenos da vacina anti-HPV em homens infectados pelo HIV. Métodos: Um total de 24 pacientes infectados pelo HIV que preencheram os critérios de inclusão durante o período de coleta foram vacinados pela vacina anti-HPV bivalente em três doses nos períodos: zero, dois e seis meses. Os grupos foram divididos em: Grupo Controle (Cinco indivíduos sadios, com sorologia negativa para HIV); Grupo A (Nove pacientes com CD4 <500 celulas mm³); Grupo B (10 pacientes com CD4 >=500 celulas mm³). Foram realizados ELISA para a detecção de anticorpos Anti-HPV nos momentos pré e pós-vacinação nos grupos estudados; posteriormente realizamos nos mesmos o ensaio de cultura celular para detecção de citocinas (IFN?, IL17, TNF, IL6 e IL10) pela técnica de CBA . Resultados: Obtivemos soroconversão da primeira dose da vacina para o grupo A 55,6%, grupo B 30%, grupo controle 60%; na segunda dose obtivemos para o grupo A 88,8%, grupo B 80%, grupo controle 80%, e por final a terceira dose no grupo A 88,8%, grupo B 90%, grupo controle 100%. A citocina IL 6 (perfil TH2) demonstrou níveis mais elevados, comparados entre os grupos A, B e grupo controle (p<0.001). A partir da 3° dose da vacinação observamos baixos níveis de INF-? (perfil TH1) A e B (p<0.0006). O grupo controle apresentou produção de INF- ? quando comparado com grupos A e B (p<0.001). Conclusão: Os pacientes soropositivos e grupo controle foram respondedores a vacinação anti-HPV. Foi demonstrada uma elevada produção das citocinas entre os grupos sugerindo uma imunomodulação do grupo HIV+. Esse trabalho apresenta informações relevantes que estimulam a realização de novos estudos nessa população, avaliações de reações cruzada da vacina que pode resultar em proteção a outros tipos de HPV não presentes na vacina, além de analisar por mais tempo as titulações no soro desses pacientes. Os dados do nosso estudo podem corroborar para a vacinação nessa população, diminuindo assim o risco de uma infecção, mortalidade e morbidade das doenças causadas pelo HPV em homens.
Introduction: Infection with Human Papilloma Virus (HPV) has been reported as one of the sexually transmitted diseases with a higher incidence nowadys, but its prevalence must be clarified in men, mainly due to low presence of symptoms. Moreover, few studies have been performed in this population until now to verify the immune response post-vaccination. The hypothesis here suggested will be the key for better understanding of the immunopathogenesis, the vaccine´s response in HIV-infected patients and collaborate in the design and strategies of vaccination against HPV in HIV-infected population. Objectives: Analyze the specific response to antigens of HPV vaccine in HIV-infected men. Methods: A total of 24 HIV-infected patients who were in accordance with the inclusion criteria during the data collection period were vaccinated with anti-HPV bivalent vaccine in three period doses: zero, two and six months. The groups were distributed in: Control group (five healthy subjects with negative serology against HIV); Group A (nine subjects with CD4 <500 cells/mm³; Group B (10 subjects with CD4 >500 cells/mm³). ELISA was performed to detect the level of antibodies anti-HPV before and after vaccination in the studied cohort. Postenarly, cells of these groups were submitted in culture to verify citokynes production (IFN?, IL17, TNF, IL6 and IL10) using CBA methodology. Results: We obtained seroconversion after the first dose of anti-HPV vaccine: control group 60%, group A 55,6% and group B 30%. In the second dose: control group 80%, group A 88,8% and Group B 80%. And at last, the third dose: Control Group 100%, Group A 88,8% and group B 90%. IL 6 citokyne (TH2 response) was detected in higher level when compared Control, A and B groups (p<0.001). IFN? citokyne (TH1 response) was detect in low level only after the third dose of vaccination, showing relevance between A and B groups (p<0.0006). Additionally, higher IFN? production was detected when compared the control with A and B groups (p<0.001). Conclusion: HIV patients and controls (HIV-) were responders to anti-HPV vaccination. It was clear that an elevated cytokine production was detected between groups, suggesting immunomodulation of HIV + group. This work suggests relevant information that challenge: new studies in this population, verification of cross-reactions of the vaccine resulting in protection of other HPV types not present in this vaccine, and analyze for longer period the titers of anti-HPV antibodies in these patients. All together, our data can corroborate for vaccination in this population, thus decreasing the risk of infection, mortality and morbidity of the disease caused by HPV in men.
APA, Harvard, Vancouver, ISO, and other styles
3

Bergstrand, Anna-Sara, and Pettersson Siri Cordes. "”Kan man skydda sig mot någon form av cancer så ska man väl det.-” : Unga vaccinerade kvinnors kunskap om Humant Papillomvirus samt kunskap om och inställning till vaccination mot Humant Papillomvirus." Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-271343.

Full text
Abstract:
Bakgrund Humant papillomvirus (HPV) orsakar vårtor och är en vanligt förekommande könssjukdom världen över. Vaccination mot de vanligaste HPV-typerna som kan orsaka kondylom och leda till cancer ingår sedan 2012 i det allmänna vaccinationsprogrammet för flickor och unga kvinnor. Tidigare forskning visar att unga kvinnor trots låg kunskap om viruset, har en positiv inställning till vaccination. Syfte Att undersöka unga vaccinerade kvinnors kunskap om HPV samt deras kunskap om och inställning till HPV-vaccination. Metod En kvalitativ explorativ studie. The Health Belief Model användes som teoretisk modell. Individuella intervjuer med åtta unga kvinnor som vaccinerats mot HPV. Data analyserades med innehållsanalys. Resultat Totalt genomfördes åtta intervjuer med unga kvinnor födda 1993-1998. Tre kategorier skapades: 1) Bristande kunskap om HPV 2) Tillförlitligt skydd mot cancer samt 3) Vaccinet är tillgängligt. Kunskapen om HPV och HPV-vaccin var låg hos de unga kvinnorna. Den främsta anledningen till att de valde att vaccinera sig var rädsla för cancer, andras inflytande till vaccinering, främst från mödrar, en tilltro till hälso- och sjukvården och till vaccinet samt att vaccinet är tillgängligt. Slutsats Det är tydligt att kunskapen om HPV och vaccinet är låg bland de deltagande unga kvinnorna. Inför framtiden behövs anpassad information till unga kvinnor om viruset och vaccinet för att tillgodose behovet av information. Det är viktigt att unga kvinnor som vaccineras mot HPV har kunskap om vaccinet för att veta hur de skyddar sig mot HPV och att de även ska förstå vikten av att gå på gynekologisk cellprovskontroll som en del av prevention av HPV.
Background Human papillomavirus (HPV) cause warts and is a common sexually transmitted infection worldwide. Vaccination against the most common HPV types that can cause genital warts and cancer is implemented in the national vaccination programme for girls and young women since 2012. Previous research shows that young women, despite low knowledge about the virus, are in favour of the vaccine. Objective To explore young vaccinated women’s knowledge about HPV and knowledge and attitudes towards HPV-vaccination. Method An qualitative explorative study. The Health Belief Model was the  theoretical framework. Individual interviews were conducted with young women vaccinated against HPV. Data were analyzed with content analyses. Results In total eight interviews were undertaken with young women born in 1993-1998. Three categories were revealed through the interviews: 1) Lack of knowledge about HPV 2) Reliable protection against cancer and 3) The vaccine is available. The young women had low knowledge about HPV and HPV vaccine. The main reasons for vaccination were; fear of cancer, influence from others, especially the mothers, trust in the healthcare and the vaccine and the vaccine is available. Conclusion The knowledge of HPV and the vaccine was low among the included women. In the future the iformation about the virus and the vaccine needs to be adapted to the young women to provide the need of information. It is important that young women who are vaccinated against HPV have knowledge about the vaccine to be able to protect themselves against HPV and that they are aware of the importance of attending future cervical cancer screening controls as a part of the prevention against HPV.
APA, Harvard, Vancouver, ISO, and other styles
4

Farfan, Arribas Diego Jose. "DNA Vaccines Against HIV-1: Augmenting Immunogenicity of gp120." Link to electronic thesis, 2002. http://www.wpi.edu/Pubs/ETD/Available/etd-0107102-160706/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Olivera-Botello, Gustavo. "Modélisation numérique des aspects immunologiques de la réaction à l’infection à HPV et de la vaccination anti-HPV par Gardasil®." Thesis, Lyon 1, 2011. http://www.theses.fr/2011LYO10038/document.

Full text
Abstract:
L’infection au papillomavirus humain (HPV) est connue pour être le principal facteur causal d’une série de maladies aussi bien bénignes (condylomatose ano-génitale, papillomatose lyringée, et autres) que malignes (cancer du col de l’utérus, certains cancers ORL, et autres). Deux vaccins prophylactiques (Gardasil® et Cervarix®) sont sur la marché depuis à peu près quatre ans pour prévenir cette infection. Le présent travail de thèse comportait trois objectifs principaux : i) étudier in-silico l’immunogénicité du vaccin Gardasil® ; ii) étudier in-silico l’histoire naturelle d’une infection à HPV et iii) évaluer in-silico le potentiel de l’hypothèse thérapeutique suivante : l’administration intramusculaire du vaccin Gardasil® chez des patients atteints d’une papillomatose laryngée induirait un effet bénéfique car l’arrivée des immunoglobulines au tissu affecté empêcherait l’HPV de compléter son cycle de vie et, par conséquent, la maladie de se propager. Les principales conclusions sont : i) pour qu’une papillomatose laryngée ne s’étende pas il faudrait, d’après nos simulations, que le taux d’IgGs sériques soit maintenu au-dessus de 200 mMU/mL ; ii) pour rester, sur une période de 10 ans, le plus longtemps possible au-dessus de ce seuil (d´effet thérapeutique), en administrant la quantité minimale de vaccin, il faudrait, d’après nos simulations, suivre le protocole suivant : l’immunisation de base (à 0, 2 et 6 mois), suivie de trois rappels successifs tous les six mois jusqu’au 24ème mois, suivis d’un rappel 18 mois plus tard ; iii) par ailleurs, il semble inutile (voire contreproductif), d’après nos simulations, de modifier le schéma traditionnel de base (0-2-6 mois)
Two prophylactic vaccines have demonstrated to prevent infections with the human papillomavirus (HPV). Thus, they have been in the market for the last four years, or so. The three main objectives of the present project were: i) to study in-silico the immunogenicity of one of these vaccines (Gardasil®); ii) to study in-silico the natural history of an HPV infection, and iii) to assess in-silico the potential of the following therapeutic hypothesis : the intramuscular administration of Gardasil® to patients already suffering from a recurrent respiratory papillomatosis would result in a better prognosis thanks to the fact that the HPV-specific immunoglobulins that would bathe the affected tissue would impede the virus to complete its life cycle and, therefore, the disease to progress. The main conclusions are: i) according to our simulations, the minimum serum IgG titer required for hampering the progression of a recurrent respiratory papillomatosis would be 200 mMU/mL ; ii) in order to keep, within a time window of ten years, the anti-HPV IgG titer over the just-mentioned therapeutic-effect threshold, the biggest possible fraction of time and through the administration of the smallest possible number of booster doses, it would be necessary, according to our simulations, to adopt the following vaccination schedule: the basic three doses (at months 0, 2 and 6), followed by three successive booster doses, every six months, until reaching the 24th month, followed by a late final booster dose, 18 months later. iii) incidentally, it would seem to be inappropriate, according to our simulations, to modify the original initial vaccination schedule (at months 0, 2 and 6)
APA, Harvard, Vancouver, ISO, and other styles
6

Ebertz, Barika. "Factors influencing women's intentions to obtain the Human Papillomavirus (HPV) vaccine." Thesis, Högskolan Kristianstad, Sektionen för hälsa och samhälle, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-10745.

Full text
Abstract:
Background: Cervical cancer is second most common cancer in women. The 15% incidence of cervical cancer in women worldwide can potentially be reduced by the vaccine against human papillomavirus (HPV). It is therefore important for all healthcare professionals including registered nurses to understand what affects women’s intentions and willingness to receive HPV vaccination so that they can overcome any inappropriate barriers and promote public health. Aim: The aim of this article was to describe factors influencing women’s intentions to obtain the HPV vaccine. Method: The following databases Cinahl, Medline, PsycINFO, Summon @ HKR and Pubmed were searched for articles that studied factors influencing women’s intention to obtain the HPV vaccine. Ten studies met the inclusion criteria, five qualitative and five quantitative. Results:  Four main categories were identified that influenced women’s intention to obtain the HPV vaccine: knowledge, attitudes, the influence of other people and the safety of the vaccine. Discussion: Better access for women to accurate information is the key to increase women’s intention to obtain the HPV vaccine and improving public health. Conclusion: Correct information about HPV and HPV virus is needed to increase women’s intention to obtain the vaccine.
Bakgrund: Cervixcancer är den näst vanligaste cancern hos kvinnor med en global incidens på15 %. Cervixcancer leder till hög mortalitet. Genom Humant Papillomvirus (HPV)-vaccinering kan incidensen minskas kraftigt. Vaccintäckningen är suboptimal på många plaster i världen. Det är viktigt att vårdpersonal, inklusive sjuksköterskor, förstår vilka faktorer som påverkar viljan och beslutet att vaccinera sig. På så sätt kan sjukvårdspersonal påverka dessa beslut och faktorer och därigenom öka vaccinationstäckningen i befolkningen. Syfte: Syftet var att beskriva faktorer som påverkar kvinnors avsikt till att vaccinera sig mot HPV. Metod: I denna allmänna litteraturstudie användes databaserna Cinahl, Medline, PsycINFO, Summon @ HKR and Pubmed för att söka efter artiklar som studerade faktorer som påverkar kvinnor att vaccinera sig mot HPV. Totalt tio artiklar inkluderades, fem kvalitativa och fem kvantitativa studier. Resultat: Fyra huvudkategorier identifierades som påverkade kvinnor att vaccinera sig mot HPV: Kunskap, attityder, andras inflytande och vaccinets säkerhet. Diskussion: Bättre tillgång till korrekt information för kvinnor om HPV-vaccinet är nyckeln till att öka kvinnors avsikt att vaccinera sig och på så sätt förbättra folkhälsan. Slutsats: Det krävs korrekt information om HPV virus och vaccin för att öka kvinnors avsikt till att vaccinera sig.
APA, Harvard, Vancouver, ISO, and other styles
7

Barley, Jessica. "Promoting HPV vaccine acceptability in men." Tallahassee, Fla. : Florida State University, 2008. http://purl.fcla.edu/fsu/lib/digcoll/undergraduate/honors-theses/341812.

Full text
Abstract:
Thesis (Honors paper)--Florida State University, 2008.
Advisor: Dr. Mary A. Gerend, Florida State University, College of Arts and Sciences, Dept. of Psychology. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
8

Busch, Marc Gregory. "Evaluation of different SIV plasmid DNA vaccines : a model for HIV vaccine development /." For electronic version search Digital dissertations database. Restricted to UC campuses. Access is free to UC campus dissertations, 2004. http://uclibs.org/PID/11984.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lundberg, Maria, and Martin Färdig. "Gymnasieelevers kunskap om och inställning till HPV och HPV-vaccin." Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-234188.

Full text
Abstract:
Bakgrund: Humant papillomvirus (HPV) är ett sexuellt överförbart vårtvirus, som kan orsaka cellförändringar och livmoderhalscancer. Tidigare forskning har visat att kunskap om HPV och HPV-vaccin generellt är låg och att vaccinationstäckningen bland unga kvinnor i många länder varit suboptimal. Syfte: Syftet med föreliggande studie var att kartlägga gymnasieelevers kunskap om och inställning till HPV och HPV-vaccin, samt undersöka om det föreligger skillnader mellan elever på praktiska och teoretiska gymnasieprogram. Metod: Studien var en deskriptiv komparativ tvärsnittsstudie med kvantitativ ansats. Orems egenvårdsteori användes som teoretisk referensram. De 230 deltagarna från fyra gymnasieskolor i Uppsala besvarade ett enkätformulär. Resultat: Majoriteten av eleverna hade generellt låg kunskap om HPV och HPV-vaccinet, hade låg tilltro till vaccinet och var osäkra på huruvida de i framtiden ville vaccineras, dock hade elever på teoretiska program bättre kunskap och mer positiv inställning än elever på praktiska program. Flickor hade bättre kunskap och om HPV och HPV-vaccin än pojkar. De flesta hade inte hört talas om vaccin mot HPV, men de allra flesta hade kännedom om vaccin mot livmoderhalscancer. Slutsats: Den låga kunskapen om HPV och HPV-vaccin kan påverka elevernas inställning samt deras intentioner att i framtiden vaccineras. Resultatet indikerar på ett behov av mer information om HPV och HPV-vaccin. Skolsköterskans hälsosamtal med gymnasieelever bör inkludera information och diskussion om HPV och HPV-vaccin anpassad för ungdomar, för att ge dem möjlighet att förstå sambandet mellan kondylom, HPV och livmoderhalscancer, och därmed lättare kunna ta ställning till vaccination.
APA, Harvard, Vancouver, ISO, and other styles
10

Frylemo, Angelica, and Emelie Karlsson. "Aspekter som påverkar vårdnadshavares beslut om HPV-vaccination : En litteraturstudie." Thesis, Högskolan Väst, Avdelningen för omvårdnad - grundnivå, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:hv:diva-16289.

Full text
Abstract:
Background: Human papillomavirus (HPV) is one of the most common sexually transmitted infections in the world and there are over 100 different varieties. Several of the varieties can lead to cancer. Although there are vaccines available, the vaccine coverage varies in the providing countries. Aim: The aim of this study was to describe aspects that make guardians choose to refrain from giving their children HPV-vaccines. Method: This Literature study is based on nine qualitative articles published between 2010 and 2020 and the articles were found in Cinahl and PubMed. Results: Guardians who refrained from the HPV-vaccine to their adolescents mentioned varied aspects. Some guardians were concerned about side effects of the vaccine and others mention a lack of knowledge and information about HPV and the vaccine. Guardians expressed concerns about vaccinating against sexually transmitted infections with their adolescents. A varied confidence in health care staff was mentioned by the guardians and they sought information from more unreliable sources such as stories from friends and family or the internet. The fact that HPV-vaccine only was provided to girls, in many of the countries, was a reason for the guardian’s skepticism. Conclusion: The result showed that there are various aspects that make guardians refrain from HPV-vaccine. Some reasons are more common in certain countries. Today's society is multicultural, which leads to a need for more studies to be done from an international perspective. Being able to meet the guardian’s various needs for information about HPV-vaccine is essential to get a higher HPV-vaccine coverage in the world.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Vaccino HPV"

1

Jha, Prabhat. The potential demand for and strategic use of an HIV-1 vaccine in Southern India. Washington, D.C: World Bank, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Young women and the HPV vaccine. New York: Rosen Pub., 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhang, Linqi, and Sharon R. Lewin, eds. HIV Vaccines and Cure. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kerns, Thomas A. Ethical Issues in HIV Vaccine Trials. London: Palgrave Macmillan UK, 1997. http://dx.doi.org/10.1057/9780230380011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ethical issues in HIV vaccine trials. Basingstoke, Hampshire: Macmillan, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ethical issues in HIV vaccine trials. New York, N.Y: St. Martin's Press, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kerns, Thomas A. Jenner on trial: An ethical examination of vaccine research in the age of smallpox and the age of AIDS. Lanham, Md: University Press of America, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Van Regenmortel, Marc H. V. HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-32459-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gotbaum, Betsy. A better shot at prevention: HPV vaccine more available at city health clinics. New York, N.Y: Office of the New York City Public Advocate, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Abalaka, Jeremiah O. A. The first decade of safe and effective HIV vaccines. Hauppauge, NY: Nova Science Publishers, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Vaccino HPV"

1

Gissmann, Lutz. "Prophylactic HPV Vaccines." In Sexually Transmitted Infections and Sexually Transmitted Diseases, 681–91. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-14663-3_51.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dudley, Matthew Z., Daniel A. Salmon, Neal A. Halsey, Walter A. Orenstein, Rupali J. Limaye, Sean T. O’Leary, and Saad B. Omer. "Human Papillomavirus (HPV)." In The Clinician’s Vaccine Safety Resource Guide, 61–68. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-94694-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Levesque, Roger J. R. "Human Papillomavirus (HPV) and HPV Vaccines." In Encyclopedia of Adolescence, 1340–42. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1695-2_435.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Levesque, Roger J. R. "Human Papillomavirus (HPV) and HPV Vaccines." In Encyclopedia of Adolescence, 1804–6. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-33228-4_435.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Heath, Ryan D., Ali Syed, Suha Abu Khalaf, and Veysel Tahan. "HIV-HBV Co-infection, Clinical Concerns." In Human Viruses: Diseases, Treatments and Vaccines, 443–56. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71165-8_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schiller, John T., and Douglas R. Lowy. "Developmental History of HPV Prophylactic Vaccines." In History of Vaccine Development, 265–84. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1339-5_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Stanley, Margaret. "Therapeutic Vaccines for HPV Infection." In HPV and Cervical Cancer, 327–39. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-1988-4_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Becker, Yechiel. "HIV—Peplotion Vaccine." In Advances in Experimental Medicine and Biology, 97–104. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-1382-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bolognesi, Dani P. "HIV Vaccines." In Immunology of HIV Infection, 561–76. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-0191-0_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dobrica, Mihaela-Olivia, Catalin Lazar, and Norica Branza-Nichita. "Production of Chimeric Hepatitis B Virus Surface Antigens in Mammalian Cells." In Vaccine Delivery Technology, 83–94. New York, NY: Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-0795-4_7.

Full text
Abstract:
Abstract The small (S) envelope protein of the Hepatitis B Virus (HBV), HBV-S, has the unique ability to self-assemble into highly immunogenic subviral particles (SVPs), in the absence of other viral factors, in eukaryotic cells, including those of nonhepatic origin. This feature is currently exploited for generation of SVPs exposing heterologous epitopes on their surface that can be used as vaccine candidates to target various diseases. Here, we describe a simple and robust method for production of such chimeric HBV-S protein-based SVPs in transiently transfected HEK293T cells and purification from cell supernatants by ultracentrifugation on sucrose cushion and sucrose step gradients. The SVPs obtained by this methodology have been successfully used in immunogenicity studies in animal models.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Vaccino HPV"

1

Krishnakumar, D., and K. S. Jaganathan. "Development of nasal HPV vaccine formulations." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685403.

Full text
Abstract:
Cervical cancer is the second most cancer in women worldwide with over 500000 new cases and 275000 deaths being registered every year. With nearly 73000 women dying every year, India now tops the world in cervical cancer deaths. India represents 26.4% of all women dying of cervical cancer globally. Cervical cancer estimated to be responsible for about 5% of human cancers worldwide. Currently available vaccines may not provide complete protection against all HPV types as the protection is primarily type specific. Furthermore, the available vaccines are delivered via intramuscular route and require three doses and require cold chain supply which increases the cost of vaccine. Therefore a single dose vaccine delivered via non-invasive route (nasal) that protects against multiple HPV types would be a cost effective and better alternative to the currently available HPV vaccines. The main objective of this study was to prepare HPV antigen loaded poly (lactic-co-glycolic acid) (PLGA) and Tri Methyl Chitosan (TMC) coated PLGA microparticles and compare their efficacy as nasal vaccine. The developed formulations were characterized for size, zeta potential, entrapment efficiency, mucin adsorption ability, in vitro and in vivo studies. PLGA microparticles demonstrated negative zeta potential whereas PLGA-TMC microparticles showed higher positive zeta potential. The protein loading efficiency was found as above 80%. Results indicated that PLGA-TMC microparticles demonstrated substantially higher mucin adsorption when compared to PLGA microparticles. HPV antigen encapsulated in PLGA-TMC particles elicited a significantly higher secretory (IgA) immune response compared to that encapsulated in PLGA particles. Present study demonstrates that PLGA-TMC microparticles with specific size range can be a better carrier adjuvant for nasal subunit vaccines. Surface modified PLGA microparticles proved great potential as a nasal delivery system for HPV infections where systemic and mucosal responses are necessary particularly in conditions after viral pathogens invade the host through the mucosal surface.
APA, Harvard, Vancouver, ISO, and other styles
2

Kumar, Anoop, Inderjit Singh Yadav, Rupinder Sekhon, Dwaipayan Bharadwaj, and Mausumi Bharadwaj. "Identification of T- and B-cell epitopes in HPV-16 E7 gene isolated from cervical cancer patients." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685256.

Full text
Abstract:
Introduction: In India, cervical cancer is the most common cancer among females. Persistence infection with high risk human papillomaviruses (HR-HPV) is an etiological agent for cervical cancer development, especially HPV-16 is found to be exclusively high in cervical cancer cases in Indian population. The continuous expression and transforming ability of HPV E7 helps in progression of cervical cancer and other HPV related disease, which make E7 as a suitable targets for the development of therapeutic vaccines. Objectives: Identification of T-& B-cell epitopes HPV-16 E7 gene isolated from in cervical cancer patients. Materials and Methods: A total of 80 cervical cancer tissue biopsies were collected and processed for DNA extraction, HPV diagnosis and genotyping. E7 gene of HPV-16 positive samples were amplified and sequenced. Epitopes in E7 gene sequence were predicted by online freely available tools. Results: In the present study we got 72 samples (90%) were positive for HPV and out of which 68 samples (94.4%) were positive for the HPV-16. HPV-16 positive samples were sequenced and translated. IEDB server was used for epitope analysis; 12 potent epitopes for the MHC-I alleles were identified in isolated E7 gene of HPV-16. The most potent epitopes were MHGDTPTLHEYM for HLA-C*07:01; LLMGTLGIVCPI for HLA-A*02:01 and MHGDTPTLHEYML for HLA-C*07:01; having percentile rank 0.2 for all three and antigencity score of 0.20011, 0.15358 and 0.10735, respectively. Conclusion: This is an effective strategy to design immuno-therapeutics and therapeutic vaccine against HPV using E7 as target. These findings will be helpful in the development of effective vaccine for particular geographical region.
APA, Harvard, Vancouver, ISO, and other styles
3

Burchell, Ann, Gina Ogilvie, Ramandip Grewal, Janet Raboud, Troy Grennan, and Irving Salit. "P5.06 Hiv-positive men’s knowledge and attitudes regarding hpv, hpv vaccine, and anal cancer screening." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.622.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sajo, E., J. Ozonu, K. Okunade, J. Ejiofor, M. Adenekan, LC Amaeshi, R. Anorlu, and S. Akanmu. "203 Knowledge and awareness of HPV and HPV vaccine among HIV positive women in lagos, nigeria." In IGCS Annual 2019 Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-igcs.203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Agulto, Aireen, Katherine Mohr, Laura Gibbons, and Robert Lancey. "HPV Vaccine Improvement QI Project." In AAP National Conference & Exhibition Meeting Abstracts. American Academy of Pediatrics, 2021. http://dx.doi.org/10.1542/peds.147.3_meetingabstract.630-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Grennan, Troy, Paul Macpherson, Ann Burchell, Marian Claudio, Joshua Edward, Jennifer Gillis, Daniel Grace, et al. "P840 The HPV screening and vaccine evaluation (HPV-SAVE) study in men living with HIV: early pathologic and acceptability outcomes." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.885.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Farache Trajano, Luiza, Rebecca Moore, and Quentin Sattentau. "The Presence of Chemical Cross-Linking Stabilises HIV-1 Envelope Glycoprotein Trimer Antigens in a Model of Intramuscular Immunisation." In Building Bridges in Medical Science 2021. Cambridge Medicine Journal, 2021. http://dx.doi.org/10.7244/cmj.2021.03.001.4.

Full text
Abstract:
Background: The HIV-1 envelope glycoprotein (Env) is the target of antigen design for antibody- based vaccination. In 2019, four trimeric Env vaccines entered an experimental trial: ConM, ConS, and their cross-linked counterparts. The trimers were formulated with MPLA adjuvant. Studies have demonstrated that adjuvants trigger neutrophil infiltration. Neutrophils activate and degranulate releasing proteases, namely elastase and cathepsinG. Aims: To assess the stability and immunogenicity of these vaccines in the presence of adjuvant- recruited neutrophils and their proteolytic enzymes. Methods: Trimers were incubated with commercially-sourced proteases. To analyse stability, samples were reduced, denatured and separated using gel electrophoresis. To assess antibody binding, a trimer-protease incubation was followed by an ELISA. To establish more physiologically relevant conditions, harvested neutrophils were exposed to various adjuvants. The supernatant, shown to contain elastase, was incubated alongside the vaccines. The reducing and denaturing gels, as well as the ELISA, was repeated. Results: Gel analysis revealed that un-crosslinked trimers underwent significant digestion whereas cross-linking conferred enhanced stability. In the presence of neutrophil-sourced protease-containing-supernatant, trimers displayed resistance to digestion. The differential stability profile of Env trimers when exposed to commercially sourced compared to supernatant- derived proteases may be due to the inhibitory effect of human serum on elastase. Antibody epitopes were maintained in vitro. Conclusion: The vaccine antigens are sensitive to enzymatic degradation. This is reduced by cross-linking and human serum.
APA, Harvard, Vancouver, ISO, and other styles
8

Tracy, J. Kathleen, Mishka Terplan, Alison D. Lydecker, and Nicholas Schluterman. "Abstract B103: HPV vaccine adherence in urban youth." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Nov 7-10, 2010; Philadelphia, PA. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1940-6207.prev-10-b103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pinto, Ligia. "Abstract SY23-02: Host immune responses to HPV and HPV vaccines." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-sy23-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tracy, J. Kathleen, Mishka Terplan, Alison D. Lydecker, and Nicholas Schluterman. "Abstract PR-11: HPV vaccine adherence in urban youth." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Nov 7-10, 2010; Philadelphia, PA. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1940-6207.prev-10-pr-11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Vaccino HPV"

1

Bingamon, Brian Michael. HIV Mosaic Vaccine. Office of Scientific and Technical Information (OSTI), December 2019. http://dx.doi.org/10.2172/1581247.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Harris, Jeffrey. The Repeated Setbacks of HIV Vaccine Development Laid the Groundwork for SARS-CoV-2 Vaccines. Cambridge, MA: National Bureau of Economic Research, March 2021. http://dx.doi.org/10.3386/w28587.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Johnston, Robert E. Attenuated VEE Vaccine Vectors Expressing HIV Immunogens. Fort Belvoir, VA: Defense Technical Information Center, September 1995. http://dx.doi.org/10.21236/ada307632.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moghtaderi, Ali, and Avi Dor. Immunization and Moral Hazard: The HPV Vaccine and Uptake of Cancer Screening. Cambridge, MA: National Bureau of Economic Research, August 2016. http://dx.doi.org/10.3386/w22523.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pisciotta, Maura. Gendering Gardasil: Framing Gender and Sexuality in Media Representations of the HPV Vaccine. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.807.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pinter, Abraham. HIV Vaccines Based on Novel MULV-HIV Fusion Proteins. Fort Belvoir, VA: Defense Technical Information Center, July 1999. http://dx.doi.org/10.21236/ada373677.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rowe, Arthur W., and Elizabeth Muchmore. Clinical Research of HIV Vaccine Studies on Chimpanzees. Fort Belvoir, VA: Defense Technical Information Center, February 1994. http://dx.doi.org/10.21236/ada278607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rowe, Arthur W., and Elizabeth Muchmore. Clinical Research of HIV Vaccine Studies on Chimpanzees. Fort Belvoir, VA: Defense Technical Information Center, April 1993. http://dx.doi.org/10.21236/ada266830.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Theva Das, Kumitaa. Computer modelling to aid search for HIV vaccine. Edited by S. Vicknesan. Monash University, April 2022. http://dx.doi.org/10.54377/e1a8-6f3e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Korber, Bette. LANL/New Mexico Consortium HIV vaccine design and Analysis. Office of Scientific and Technical Information (OSTI), July 2014. http://dx.doi.org/10.2172/1136461.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Vaccino HPV' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography